CD8A-binding fibronectin type III domains

Patent metadata

Field	Value
Publication number	US-11299534-B2
Application number	US-202016821064-A
Country	US
Kind code	B2
Filing date	Mar 17, 2020
Priority date	Dec 14, 2016
Publication date	Apr 12, 2022
Grant date	Apr 12, 2022

Abstract

Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

First claim

What is claimed:

1. A protein comprising the amino acid sequence of SEQ ID NO 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, or SEQ ID NO: 234.

2. The protein of claim 1 , wherein the protein comprises the amino acid of SEQ ID NO: 229.

3. The protein of claim 1 , wherein the protein comprises the amino acid of SEQ ID NO: 230.

4. The protein of claim 1 , wherein the protein is conjugated to a second molecule.

5. The protein of claim 1 , wherein the protein comprises the amino acid of SEQ ID NO: 231.

6. The protein of claim 1 , further comprising a methionine at the N-terminus of the protein.

7. The protein of claim 1 , wherein the protein is coupled to a half-life extending moiety.

8. The protein of claim 7 , wherein the half-life extending moiety is albumin, an albumin binding molecule, a polyethylene glycol (PEG), or an Fe region of an immunoglobulin.

9. A capture agent comprising the protein of claim 1 .

10. The protein of claim 4 , wherein the second molecule is a detectable label.

11. The protein of claim 10 , wherein the detectable label is selected from a group consisting of radioactive isotope, magnetic beads, metallic beads, colloidal particles, a fluorescent dye, an electron-dense reagent, an enzyme, biotin, digoxigenin, and hapten.

12. The protein of claim 4 , wherein the second molecule is a cytotoxic agent.

13. The protein of claim 4 , wherein the second molecule is a chelator.

14. The protein of claim 4 , wherein the second molecule is a nucleic acid molecule.

15. The protein of claim 1 , wherein the protein comprises the amino acid of SEQ ID NO: 232.

16. The protein of claim 1 , wherein the protein comprises the amino acid of SEQ ID NO: 234.

17. A composition comprising the protein of claim 1 .

18. A composition comprising the protein of claim 12 .

19. A composition comprising the protein of claim 13 .

20. A composition comprising the protein of claim 14 .

Assignees

• Janssen Biotech Inc

Inventors

• Hawkins Rebecca
• Jacobs Steven
• Sepulveda Manuel

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/575

  for cancer · CPC title

• G01N2333/78

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title

• G01N2333/70517

  CD8 · CPC title

• G01N33/6887

  from muscle, cartilage or connective tissue · CPC title